First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)-Reference-Cited by-同舟云学术

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)

Published:2015-06 Issue:6 Volume:26 Page:1123-1128
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ravaud A.,Oudard S.,De Fromont M.,Chevreau C.,Gravis G.,Zanetta S.,Theodore C.,Jimenez M.,Sevin E.,Laguerre B.,Rolland F.,Ouali M.,Culine S.,Escudier B.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/6/1123/16700094/mdv149.pdf

Reference31 articles.

1. Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features;Renshaw;Am J Surg Pathol,1997

2. Cytogenetics of papillary renal cell tumors;Kovacs;Genes Chromosomes Cancer,1991

3. Studying cancer families to identify kidney cancer genes;Zbar;Annu Rev Med,2003

4. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases;Amin;Am J Surg Pathol,2002

5. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification;Pignot;Urology,2007

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma;Journal of Clinical Oncology;2024-09-10

2. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances;American Society of Clinical Oncology Educational Book;2024-06

3. Exploring genes within the glutathione peroxidase family as potential predictors of prognosis in papillary renal cell carcinoma;Oncologie;2024-05-08

4. Papillary Renal Cell Carcinoma: Current Evidence and Future Directions;Kidney Cancer;2024-05-07

5. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study;European Urology Oncology;2024-04